Antenatal glucocorticoid treatment and polymorphisms of the glucocorticoid and mineralocorticoid receptors are associated with IQ and behavior in young adults born very preterm

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 500-507

  Van Der Voorn, Bibian ^a   Wit, Jan M ^b   Van Der Pal, Sylvia M ^c   Rotteveel, Joost ^a   Finken, Martijn J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; GLUCOCORTICOID;

ADULT; ARTICLE; BEHAVIOR ASSESSMENT; CONTROLLED STUDY; DIGITAL MULTICULTURAL CAPACITY TEST; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GESTATIONAL AGE; GLUCOCORTICOID RECEPTOR GENE; HETEROZYGOTE; HUMAN; INFANT; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; MINERALOCORTICOID RECEPTOR GENE; PREGNANCY OUTCOME; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SENSITIVITY ANALYSIS; SEX RATIO; SMALL FOR DATE INFANT; SOCIAL BEHAVIOR; YOUNG ADULT BEHAVIOR CHECKLIST; YOUNG ADULT SELF REPORT; AGGRESSION; ANXIETY; DEPRESSION; DRUG EFFECTS; GENE FREQUENCY; GENETICS; INTELLIGENCE TEST; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; PSYCHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

AGGRESSION; ANXIETY; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; GLUCOCORTICOIDS; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INTELLIGENCE TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; YOUNG ADULT;

EID: 84922573074     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2843     Document Type: Article

References (40)

1. de Kieviet JF, Zoetebier L, van Elburg RM, Vermeulen RJ, Oosterlaan J. Brain development of very preterm and very low-birthweight children in childhood and adolescence: A meta-analysis. Dev Med Child Neurol. 2012; 54(4): 313-23.
2. Aylward GP Neurodevelopmental outcomes of infants born prematurely. J Dev Behav Pediatr. 2005; 26(6): 427-40.
3. Connors SL, Levitt P, Matthews SG, et al. Fetal mechanisms in neurodevelopmental disorders. Pediatr Neurol. 2008; 38(3): 163-176.
4. Khulan B, Drake AJ. Glucocorticoids as mediators of developmental programming effects. Best Pract Res Clin Endocrinol Metab. 2012; 26(5): 689-700.
5. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006; (3): CD004454. Updated version (2013).
6. Dessens A, Haas HS, Koppe J. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics. 2000; 105(6): E77.
7. Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: Psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ. 2005; 331(7518): 665.
8. MacArthur BA, Howie R, Dezoete J, Elkins J. Cognitive and psychosocial development of 4-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics. 1981; 68(5): 638-643.
9. Bethesda MD Effects of antenatal dexamethasone administration in the infant: Long-term follow-up. J Pediatr. 1984; 104(2): 259-267.
10. Salokorpi T, Sajaniemi N, Hällback H, Kari A, Rita H, von Wendt L. Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatr. 1997; 86(3): 294-298.
11. Derijk RH Single nucleotide polymorphisms related to HPA axis reactivity. Neuroimmunomodulation. 2009; 16(5): 340-352.
12. Matthews SG Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res. 2000; 47(3): 291-300.
13. Kang HJ, Kawasawa YI, Cheng F, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011; 478(7370): 483-489.
14. Kuningas M, de Rijk RH, Westendorp RG, Jolles J, Slagboom PE, van Heemst D. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. Neuropsychopharmacology. 2007; 32(6): 1295-1301.
15. Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EFC. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci. 2009; 1179: 179-198.
16. Russcher H, Smit P, van den Akker EL, et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab. 2005; 90(10): 5804-5810.
17. van Leeuwen N, Kumsta R, Entringer S, et al. Functional mineralo-corticoid receptor (MR) gene variation influences the cortisol awakening response after dexamethasone. Psychoneuroendocrinology. 2010; 35(3): 339-349.
18. Veen S, Ens-Dokkum MH, Schreuder AM, Verloove-Vanhorick SP, Brand R, Ruys JH. Impairments, disabilities, and handicaps of very preterm and very-low-birthweight infants at five years of age. The Collaborative Project on Preterm and Small for Gestational Age Infants (POPS) in The Netherlands. Lancet. 1991; 338: 33-36.
19. Hille ET, Elbertse L, Gravenhorst JB, Brand R, Verloove-Vanhorick SP. Nonresponse bias in a follow-up study of 19-year-old adolescents born as preterm infants. Pediatrics. 2005; 116(5): e662-e666.
20. Vandenbroucke JP When are observational studies as credible as randomised trials? Lancet. 2004; 363(9422): 1728-1731.
21. Finken MJ, Keijzer-Veen MG, Dekker FW, et al. Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation. Arch Dis Child Fetal Neonatal Ed. 2008; 93(6): F442-F447.
22. Bleichrodt N, van den Berg RH. Multicultural Capacity Test: Intermediate Level (MCT-M) Manual. Amsterdam, Netherlands: NOA-VU 2000.
23. Hille ET, Dorrepaal C, Perenboom R, Gravenhorst JB, Brand R, Verloove-Vanhorick SP. Social lifestyle, risk-taking behavior, and psychopathology in young adults born very preterm or with a very low birthweight. J Pediatr. 2008; 152(6): 793-800, 800.e1-e4.
24. Hille ET, Weisglas-Kuperus N, van Goudoever JB, et al. Functional outcomes and participation in young adulthood for very preterm and very low birth weight infants: The Dutch Projecton Preterm and Small for Gestational Age Infants at 19 years of age. Pediatrics. 2007; 120(3): e587-e595.
25. van Rossum EF, Koper JW, Huizenga NA, et al. Apolymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes. 2002; 51(10): 3128-3134.
26. Huizenga NA, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab. 1998; 83(1): 144-151.
27. Nosarti C. Structural and functional brain correlates of behavioral outcomes during adolescence. Early Hum Dev. 2013; 89(4): 221-227.
28. Hack M. Young adult outcomes of very-low-birth-weight children. Semin Fetal Neonatal Med. 2006; 11(2): 127-137.
29. Coe CL, Lubach GR. Developmental consequences of antenatal dexamethasone treatment in nonhuman primates. Neurosci Biobehav Rev. 2005; 29(2): 227-235.
30. Noorlander CW, De Graan PN, Middeldorp J. Ontogeny of Hippocampal Corticosteroid Receptors: Effects of Antenatal Glucocorticoids in Human and Mouse. J Comp Neurol. 2006; 499(6): 924-932.
31. Uno H, Eisele S, Sakai A, et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav. 1994; 28(4): 336-348.
32. Meijer OC, de Kloet ER Corticosterone and serotonergic neurotransmission in the hippocampus: Functional implications of central corticosteroid receptor diversity. Crit Rev Neurobiol. 1998; 12(1-2): 1-20.
33. Dean F, Matthews SG. Maternal dexamethasone treatment in late gestation alters glucocorticoid and mineralocorticoid receptor mRNA in the fetal guinea pig brain. Brain Res. 1999; 846(2): 253-259.
34. Finken MJJ, Meulenbelt I, Dekker FW, et al. The 23K variant of the R23K polymorphism in the glucocorticoid receptor gene protects against postnatal growth failure and insulin resistance after preterm birth. J. Clin Endocrinol Metab. 2007; 92(12): 4777-4782.
35. van Rossum EF, Feelders RA, van den Beld AW, et al. Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. Am J Med. 2004; 117(3): 158-162.
36. Derijk RH, de Kloet ER Corticosteroid receptor polymorphisms: Determinants of vulnerability and resilience. Eur J Pharmacol. 2008; 583(2-3): 303-311.
37. Melcescu E, Griswold M, Xiang L, et al. Prevalence and cardiometabolic associations of the glucocorticoid receptor gene polymorphisms N363S and BclI in obese and non-obese black and white Mississippians. Hormones (Athens). 2012; 11(2): 166-177.
38. Quax RA, Manenschijn L, Koper JW, et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol. 2013; 9(11): 670-686.
39. Saigal S, Rosenbaum P, Feeny D, et al. Parental perspectives of the health status and health-related quality of life of teen-aged children who were extremely low birth weight and term controls. Pediatrics. 2000; 105(3 Pt 1): 569-574.
40. van Rossum EF, Voorhoeve PG, te Velde SJ, et al. The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J Clin Endocrinol Metab. 2004; 89(8): 4004-4009.